Zai Lab Announces Updates to China's National Reimbursement Drug List

Core Insights - Zai Lab Limited announced the renewal of several medicines in the 2025 National Reimbursement Drug List (NRDL) by China's National Healthcare Security Administration (NHSA) [1] Group 1: Medicines and Indications - VYVGART® (efgartigimod alfa injection) is renewed for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive [1] - NUZYRA® (omadacycline) has also been included in the renewed list, indicating continued support for its use in specific indications [1]